5 STAR Google REVIEWS
Personalized integrative medical care for weight management, GLP-1 support, peptide therapy, hormone health, regenerative medicine and healthy aging.
Director, Optimal Health Medical, LLC
Dr. Henry C. Sobo, M.D., is the Director of Optimal Health Medical, LLC in Stamford, Connecticut. He completed his Internal Medicine residency at Maimonides Medical Center in Brooklyn in 1985 and has decades of experience caring for patients using conventional and integrative approaches.
Professional Affiliations and Expertise
Dr. Sobo has longstanding experience in physician-guided weight management and was first board-certified by the American Board of Bariatric Medicine in 1990. His practice today includes medical weight management, peptide therapy, hormone health, regenerative medicine, IV therapies and individualized integrative medical care.
Dr Sobo was first Board Certified in Weight Loss Medicine by the American Board of Bariatric Medicine in 1990. He dedicates his time, profession, and expertise to help patients looking to lose weight most effectively and safely. epending on diagnosis, treatment goals and clinical appropriateness, weight-management medications may include semaglutide or tirzepatide. Brand names and FDA-approved indications vary by medication and condition.
GLP-1–based medications can support weight management in appropriate patients by affecting appetite, satiety and metabolic signaling. Some semaglutide and tirzepatide products have FDA-approved indications for chronic weight management in specific patient populations. Medication choice, dosing and monitoring should be individualized by a qualified healthcare professional.
Dr. Sobo evaluates peptide therapy within an individualized medical treatment plan based on a patient’s goals, medical history and clinical appropriateness. Evidence varies significantly among peptide compounds and potential uses; some applications remain investigational and should not be interpreted as established clinical benefits. When appropriate, peptide therapy may be considered alongside other physician-guided approaches such as PRP and broader regenerative care. Explore Peptide Therapy and Learn About PRP Treatments
A new systematic review and updated orthopedic guidance create timely, local treatment-intent content. This article was evidence-checked on September 6, 2026. Regulatory status, labels, and trial publications can change; verify
Forzinity FDA approval has created understandable questions about elamipretide, Barth syndrome and products marketed as “SS-31.” The central distinction is straightforward: the FDA approved a specific elamipretide product for a
Phase 3 head-to-head results and an anticipated late-2026 FDA decision create strong news and comparison intent. This article was evidence-checked on September 6, 2026. Regulatory status, labels, and trial publications
